மருத்துவ புற்றுநோயியல் ஆண்டு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Business Wire. The AP news staff was not involved in its creation. BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Esophageal Squamous Cell Carcinoma (ESCC) July 8, 2021 GMT CAMBRIDGE, Mass. & BEIJING (BUSINESS WIRE) Jul 7, 2021 BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a supplemental Biologics License Application (sBLA) for anti-PD1 antibody tislelizumab for the treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have disease progression following or are intolerant to first-line standard chemotherapy.

United kingdomUnited statesGabrielle zhouYong benBeigene ltdExchange commissionAmerican society of clinical oncology annual meetingTislelizumab clinical programChina national medical products administrationInternational agency for research on cancerBristol myers squibbHealth commissionDrug evaluationBiologics license applicationChief medical officerNorth america